Загрузка...
Immunomodulatory Therapy for Melanoma: Ipilimumab and Beyond
In 2011, the FDA approved the first new therapy for melanoma in over a decade, ipilimumab (Yervoy). Ipilimumab is a novel antibody that blockscytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a regulatory molecule expressed on activated T cells. Blockade of this important immune checkpoint can l...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3653249/ https://ncbi.nlm.nih.gov/pubmed/23438382 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clindermatol.2012.08.006 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|